Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Laboratorios Farmaceuticos Rovi's average Free Cash Flow per Share Growth Rate was 42.30% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -12.50% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 42.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Laboratorios Farmaceuticos Rovi was 103.30% per year. The lowest was -31.00% per year. And the median was 9.50% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Laboratorios Farmaceuticos Rovi 3-Year FCF Growth Rate Related Terms
LABFF vs ZTS, UTHR, VTRS: 3-Year FCF Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi 3-Year FCF Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of -12.50% mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a 3-Year FCF Growth Rate of -12.50% as of Mar. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Laboratorios Farmaceuticos Rovi and its competitors. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #478 out of 658 companies in the Drug Manufacturers industry, placing it in the top 72.6%.
Is Laboratorios Farmaceuticos Rovi's 3-Year FCF Growth Rate too high?
Laboratorios Farmaceuticos Rovi's current 3-Year FCF Growth Rate is -12.50%. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #478 out of 658 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's 3-Year FCF Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #478 out of 658 companies for 3-Year FCF Growth Rate. This places Laboratorios Farmaceuticos Rovi in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 8.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Drug Manufacturers company?
The median 3-Year FCF Growth Rate among Drug Manufacturers companies is 8.85, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median 3-Year FCF Growth Rate is 8.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current 3-Year FCF Growth Rate is -12.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current 3-Year FCF Growth Rate of -12.50%. The stock's GF Value™ is $85.32, compared to a current price of $90.61 — trading 6.2% above its estimated fair value. The current 3-Year FCF Growth Rate is -12.50%. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current 3-Year FCF Growth Rate is -12.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 6.2% above its estimated GF Value™ of $85.32.
Key valuation signals for LABFF:
3-Year FCF Growth Rate: -12.50%
GF Value™: $85.32 vs. price of $90.61 (6.2% above fair value)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
89GF Score
Get the complete analysis for LABFF
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
